Sangui Biotech International, Inc. (SGBI)

[funnyG986]

SGBI news 11/25/2016

Sangui BioTech International Inc .: New expert consensus underscores the outstanding effect of granulox in chronic wounds

Sangui BioTech International Inc. / Key word (s): Miscellaneous Sangui BioTech International Inc .: New expert consensus underlines the outstanding effects of granulox on chronic wounds

25.11.2016 / 11:19 The issuer is solely responsible for the content of this announcement.

Sangui BioTech:

- New expert consensus underlines the outstanding effect of granulox in chronic wounds

Witten, 25.11.2016:

In the edition 5/2016 of the specialist magazine "Wundmanagement" (Wundmanagement 2016; 5: 276-284), the official notification body of the initiative Chronic Wounds eV (ICW eV), the "expert conscience is to practice-relevant aspects of the wound therapy with a hemoglobin spray "Has been published. This publication is another proof that the wound spray Granulox contributes to a faster wound healing.

The recommendation was recommended by well-known experts from the DACH region. Prof. Dr. med. Joachim Dissemond, board member of ICW eV and head of ICW-certified dermatological wound care at the university hospital in Essen, Veronika Gerber, first chairman of ICW eV, Prof. Dr. Knut Kröger, deputy chairman of ICW As well as specialist author and speaker for wound care concepts Kerstin Protz.

Austria is represented by Prim. Univ. Prof. Dr. med. Robert Strohal and the Wound Care Manager Peter Kurz. PD Dr. med. Severin Läuchli, acting president of the European Wound Management Association (EWMA) and head of dermatology at the University of Zurich and Siegfried Uttenweiler are responsible for the Swiss vote.

The outstanding contribution not only considers the well-known methods and possible product combinations of Granulox. He is also dedicated to presenting the novel MOIST concept for the local treatment of chronic wounds. For the first time, oxygen as well as further substances or methods with a supporting effect, such as growth factors, are included in the existing concept for the local therapy of chronic wounds. This is a milestone for the importance of oxygen in the area of ??wound healing. The expert consensus also shows a clear and precise application algorithm for granulox. Accordingly, Granulox should be used every three days for both acute and chronic wounds that have not decreased by at least 40% after four weeks of conventional treatment and thus meet the criterion of slowed wound healing. Healing progress should be reevaluated at 4-week intervals or in the event of complications.

It is clear from the expert consensus that granulox is well suited to provide wounds with additional oxygen. In addition, the healing processes can be promoted in hypoxic wounds, especially if a sufficient improvement in wound healing by standard therapies could not be achieved. Thus the publication once again shows that Granulox should be integrated as a treatment method in the care of chronic wounds.

"We are delighted that such a high-caliber international expert group emphasizes the role of Granulox in modern wound treatment and calls for a systematic use in ill-healing wounds," commented Michael Sander, Managing Director of Sastomed GmbH, to whom Sangui BioTech GmbH has the worldwide distribution rights For the wound spray granulox. The full article can be downloaded at http://granulox.de/downloads/Wundmanagement_5_2016_Konsensus_DE.pdf.

Sangui BioTech International, Inc. ( "SGBI") is a holding company whose shares are traded on OTCQB (www.otcmarkets.com: SGBI) and in the free circulation of the stock exchanges in Berlin and Hamburg-Hannover (www.boersenag.de: SBH) will. Its business purpose is to raise funds and secure access to the capital market for Sangui Group companies. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui Biotech International, Inc.

Further information: Sangui Biotech International, Inc. Thomas Striepe Fax: [phone] E-Mail: [e-mail]



http://www.finanznachrichten.de/nachrichten-2016-11/39286960-dgap-news-sangui-biotech-international-inc-neuer-expertenkonsens-unterstreicht-die-herausragende-wirkung-von-granulox-bei-chronischen-wunden-deuts-016.htm